Maddyness

LabGenius Closes $15M Series A Extension, led by Atomico

Comments
Share :
Up
Previous part
1 —
Next part
Down
Maddyness
Up
Menu
Part 1
Down
Finance

LabGenius Closes $15M Series A Extension, led by Atomico

201 - trending  |  
Comments
By Maddyness - 30 October 2020 / 07H15 - Updated 29 October 2020

LabGenius has closed an oversubscribed $15M extension round, led by Atomico, to support the company’s mission of dramatically improving the discovery process for new protein therapeutics.

Since the first protein therapeutic was approved almost 40 years ago, this class of molecules has been used to treat both life-threatening conditions like cancer and chronic diseases like diabetes. Protein therapeutics represent 30% of total pharmaceutical sales. Yet high costs, risks and long timeframes associated with their development has limited the ability to bring new treatments to market. Today, getting just one new protein therapeutic to market costs the industry in excess of a billion pounds and can take more than a decade. LabGenius is building a systematic, machine learning-driven platform that will make the discovery of protein therapeutics faster and yield novel drugs that would not have been found using traditional methods.

The additional capital brings the company’s total Series A funding to $25M and will be used to increase investment into LabGenus’ underlying technology platform and product pipeline. As part of this financing, Atomico Partner Irina Haivas will join the board.

“To add a fund of Atomico’s calibre and reputation to our investor base is a huge win for LabGenius. Atomico’s operational experience is second to none and they are the perfect partner to help us scale a global company from Europe. In addition, the confidence that Lux, Obvious, Kindred and Inovia have demonstrated in doubling down in this round reflects the tremendous technical progress that the team has made over the past 12 months.” – James Field, founder and CEO of LabGenius

LabGenius’ platform which combines, into a closed loop, robotic automation, synthetic biology and machine learning enables the team to systematically search through billions of potential protein designs and rapidly test those that are predicted to be high performing. Ultimately, the company’s technology will help slash the time, cost and risk associated with developing new drugs.

“The human and economic toll of COVID-19 makes it painfully obvious that we need a faster and better way to develop drugs. R&D in the industry reached a productivity bottleneck many years ago; the only way forward is through technology. LabGenius is taking on the task of applying software and engineering to biology, and doing this in an area of high complexity: proteins. We believe they have the best technical approach, and have been impressed by the team’s ability to execute and attract incredible talent. We’re excited to work with James and the team on their journey to change the industry paradigm” – Irina Haivas, Partner at Atomico

Read also
By

Maddyness

30 October 2020 / 07H15
Updated 29 October 2020
Most read articles of the moment

Self-care, working smart, and picking your battles - key tips for startup success

Entrepreneurs
By Maddyness, with HSBC Private Banking - 12H30Monday 16 November 2020
Next

Breakfast of Champions: Interview with Alexandre Sagakian

Entrepreneurs
By Alexandre Sagakian - 07H00Tuesday 24 November 2020
Next

Attracting Black Talent with Emma Philips, Partner, LocalGlobe

Finance
By Emma Philips - 07H00Monday 16 November 2020
Next

Modernising insurance: Interview with Risto Rossar, CEO Insly

Technology
By Risto Rossar - 07H00Wednesday 25 November 2020
Next
Business
Menu
Entrepreneurs
Menu
Finance
Menu
Innovation
Menu
Technology
Menu
Agenda
Calendar
MaddyEvent
MaddyEvent
MaddyStudio
MaddyStudio
Search
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Most viewed articles
Newsletter
About
Legal Information
Search
Our services
Categories
Maddynews
Hmm ... There's a problem :(
Maddyness

Comme vous le savez, Maddyness est à la pointe de l'innovation.
Malheureusement il semble que votre navigateur ne le soit pas encore...

Pour une bonne expérience de navigation
(et être au top de la modernité) pensez à passer sur :
Chrome
Chrome
Safari
Safari
Firefox
Firefox
Edge
Edge